I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 6 studies | 26% ± 5% | |
| macrophage | 6 studies | 20% ± 5% | |
| microglial cell | 5 studies | 24% ± 5% | |
| CD16-negative, CD56-bright natural killer cell, human | 4 studies | 24% ± 5% | |
| epithelial cell | 4 studies | 24% ± 5% | |
| astrocyte | 4 studies | 21% ± 4% | |
| endothelial cell | 4 studies | 21% ± 4% | |
| leukocyte | 3 studies | 23% ± 8% | |
| CD16-positive, CD56-dim natural killer cell, human | 3 studies | 21% ± 3% | |
| myeloid cell | 3 studies | 21% ± 5% | |
| lymphocyte | 3 studies | 22% ± 4% | |
| gamma-delta T cell | 3 studies | 23% ± 3% | |
| mature NK T cell | 3 studies | 17% ± 2% | |
| GABAergic neuron | 3 studies | 27% ± 9% | |
| glutamatergic neuron | 3 studies | 33% ± 12% | |
| oligodendrocyte precursor cell | 3 studies | 19% ± 2% | |
| endothelial cell of lymphatic vessel | 3 studies | 19% ± 5% | |
| plasmacytoid dendritic cell | 3 studies | 19% ± 3% |
